Drug Discovery – Page 17

Poor hit-to-lead progression during early discovery – decision framework regulators expect

During the early phases of drug discovery, various signals may indicate poor hit-to-lead progression. These could manifest as discrepancies in assay results, delayed project timelines, or unfavorable pharmacokinetic properties. Here…

Target validation uncertainty during portfolio review – how to avoid late-stage attrition

The first step in addressing target validation uncertainty is to clearly define the symptoms that indicate a problem. Symptoms may arise from various sources within your project portfolio, including:Click to…

Off-target toxicity signals before IND-enabling studies – data package strengthening approach

Detection of off-target toxicity primarily occurs through unforeseen adverse signals during preclinical testing. These signals can manifest in various ways:Click to read the full article.

ADME liabilities identified late during translational assessment – how to avoid late-stage attrition

Identifying the initial symptoms or signals that indicate late-stage ADME liabilities is crucial in the drug discovery process. Common signals include:Click to read the full article.

Poor hit-to-lead progression during translational assessment – impact on IND success probability

Identifying the signs of poor hit-to-lead progression starts with recognizing abnormal signals during preclinical studies and translational assessments. Common symptoms include:Click to read the full article.

Target validation uncertainty during regulatory interaction preparation – how to avoid late-stage attrition

The first step in addressing target validation uncertainty is to recognize the symptoms or signals that indicate potential issues. Typical signs that may arise include:Click to read the full article.

Reproducibility issues in screening data during regulatory interaction preparation – impact on IND success probability

The first step in addressing reproducibility issues is to recognize the symptoms or signals indicating that something is amiss during the screening processes. These symptoms may manifest in various forms:Click…

Reproducibility issues in screening data during regulatory interaction preparation – decision framework regulators expect

Identifying symptoms of reproducibility issues is essential for timely intervention. Common signals include:Click to read the full article.

Tips for Drug Discovery

Poor hit-to-lead progression during early discovery – decision framework regulators expect

Target validation uncertainty during portfolio review – how to avoid late-stage attrition

Off-target toxicity signals before IND-enabling studies – data package strengthening approach

ADME liabilities identified late during translational assessment – how to avoid late-stage attrition

Poor hit-to-lead progression during translational assessment – impact on IND success probability

Target validation uncertainty during regulatory interaction preparation – how to avoid late-stage attrition

Reproducibility issues in screening data during regulatory interaction preparation – impact on IND success probability

Reproducibility issues in screening data during regulatory interaction preparation – decision framework regulators expect

Reproducibility issues in screening data during early discovery – decision framework regulators expect

Reproducibility issues in screening data during regulatory interaction preparation – risk mitigation strategy

Reproducibility issues in screening data before IND-enabling studies – data package strengthening approach

Off-target toxicity signals before IND-enabling studies – how to avoid late-stage attrition